New Cancer Drug Doubles Survival Rate for Pancreatic Cancer

A recent study has shown that a new cancer medication has doubled the survival time for patients suffering from pancreatic cancer, one of the deadliest forms of cancer. This breakthrough could significantly impact treatment protocols and patient outcomes in Switzerland and beyond. The development of this therapy marks a significant advancement in oncology, particularly for a cancer type that has historically had limited treatment options.